DE2815926A1 - Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel - Google Patents

Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel

Info

Publication number
DE2815926A1
DE2815926A1 DE19782815926 DE2815926A DE2815926A1 DE 2815926 A1 DE2815926 A1 DE 2815926A1 DE 19782815926 DE19782815926 DE 19782815926 DE 2815926 A DE2815926 A DE 2815926A DE 2815926 A1 DE2815926 A1 DE 2815926A1
Authority
DE
Germany
Prior art keywords
group
oxy
hydrogen
carbazolyl
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19782815926
Other languages
German (de)
English (en)
Inventor
Karl Prof Dr Med Dietmann
Wolfgang Dr Rer Nat Kampe
Egon Dr Med Roesch
Gisbert Dr Med Sponer
Max Dr Rer Nat Thiel
Fritz Dr Phil Wiedemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6036838&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE2815926(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DE19782815926 priority Critical patent/DE2815926A1/de
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Priority to CA324,667A priority patent/CA1129416A/en
Priority to DK141979A priority patent/DK154555C/da
Priority to FI791142A priority patent/FI70406C/fi
Priority to SU792745301A priority patent/SU810079A3/ru
Priority to ES479396A priority patent/ES479396A1/es
Priority to AU45820/79A priority patent/AU522975B2/en
Priority to DE7979101063T priority patent/DE2960553D1/de
Priority to EP79101063A priority patent/EP0004920B1/de
Priority to IL57020A priority patent/IL57020A/xx
Priority to DD79212096A priority patent/DD143607A5/de
Priority to CS792434A priority patent/CS227007B2/cs
Priority to ZA791732A priority patent/ZA791732B/xx
Priority to JP4311979A priority patent/JPS54157558A/ja
Priority to AT0276279A priority patent/AT375639B/de
Priority to HU79BO1774A priority patent/HU179433B/hu
Publication of DE2815926A1 publication Critical patent/DE2815926A1/de
Priority to CS792434A priority patent/CS227047B2/cs
Priority to US06/479,921 priority patent/US4503067A/en
Priority to SG52284A priority patent/SG52284G/en
Priority to HK23/85A priority patent/HK2385A/xx
Priority to JP62076548A priority patent/JPS63258416A/ja
Priority to CS914200A priority patent/CS420091A3/cs
Priority to MX9203380A priority patent/MX9203380A/es
Priority to LV930454A priority patent/LV5234A3/xx
Priority to LU88320C priority patent/LU88320I2/de
Priority to NL930110C priority patent/NL930110I2/nl
Priority to LTRP1124A priority patent/LT2628B/xx
Priority to BG098612A priority patent/BG61419B2/bg
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE19782815926 1971-10-29 1978-04-13 Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel Withdrawn DE2815926A1 (de)

Priority Applications (28)

Application Number Priority Date Filing Date Title
DE19782815926 DE2815926A1 (de) 1978-04-13 1978-04-13 Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
CA324,667A CA1129416A (en) 1978-04-13 1979-04-02 Carbazolyl-(4)-oxypropanolamine derivatives
DK141979A DK154555C (da) 1978-04-13 1979-04-06 Analogifremgangsmaade til fremstilling af carbazolyl-(4)-oxy-propanolaminderivater eller deres farmakologisk anvendelige salte
FI791142A FI70406C (fi) 1978-04-13 1979-04-06 Foerfarande foer framstaellning av farmaceutiskt aktivt karbazolyl-(4)-oxipropanolamin-derivat
SU792745301A SU810079A3 (ru) 1978-04-13 1979-04-06 Способ получени производныхКАРбАзОлил (4)-ОКСи-пРОпАНОлАМиНАили иХ СОлЕй (ЕгО ВАРиАНТы)
ES479396A ES479396A1 (es) 1978-04-13 1979-04-06 Procedimiento para la preparacion de derivados de carbazolil-(4)-oxi-propanolamina.
AU45820/79A AU522975B2 (en) 1978-04-13 1979-04-06 Carbazolyl-(4)-oxypropanolamine derivatives
DE7979101063T DE2960553D1 (en) 1978-04-13 1979-04-07 Derivatives of carbazolyl-4-oxypropanolamine, methods for their preparation and medicines containing them
EP79101063A EP0004920B1 (de) 1978-04-13 1979-04-07 Carbazolyl-(4)-oxy-propanolamin-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
IL57020A IL57020A (en) 1978-04-13 1979-04-08 Carbazolyl-(4)-oxypropanolamine derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
DD79212096A DD143607A5 (de) 1978-04-13 1979-04-09 Verfahren zur herstellung neuer carbazolyl-(4)-oxy-propanolamin-derivate
CS792434A CS227007B2 (en) 1978-04-13 1979-04-10 Method of preparing carbazol-4-yl oxypropanolamine derivatives
ZA791732A ZA791732B (en) 1978-04-13 1979-04-11 Carbazolyl-(4)-oxypropanolamine derivatives,preparation thereof and pharmaceutical compositions containing these compounds
JP4311979A JPS54157558A (en) 1978-04-13 1979-04-11 Novel carbazolyll*4**oxyypropanolamine derivative*its manufacture and drug containing it and having vasodilatation and*or betaaacceptor occlusion activity
HU79BO1774A HU179433B (en) 1978-04-13 1979-04-12 Process for preparing new carbazolyl-/4/-oxy-propanolamine derivatives and pharmaceutical compositions containing thereof
AT0276279A AT375639B (de) 1978-04-13 1979-04-12 Verfahren zur herstellung von neuen carbazolyl-(4)-oxy-propanolamin-derivaten und ihren salzen
CS792434A CS227047B2 (cs) 1978-04-13 1982-08-20 Způsob výroby derivátů karbazol-4-yloxypropanolaminu
US06/479,921 US4503067A (en) 1978-04-13 1983-04-04 Carbazolyl-(4)-oxypropanolamine compounds and therapeutic compositions
SG52284A SG52284G (en) 1978-04-13 1984-07-20 Derivatives of carbazolyl-4-oxypropanolamine,methods for their preparation and medicines containing them
HK23/85A HK2385A (en) 1978-04-13 1985-01-10 Derivatives of carbazolyl-4-oxypropanolamine, methods for their preparation and medicines containing them
JP62076548A JPS63258416A (ja) 1978-04-13 1987-03-31 カルバゾリル−（４）−オキシ−プロパノ−ルアミン誘導体を含有し血管拡張作用及び／又はβ−受容体閉塞作用を有する薬剤
CS914200A CS420091A3 (en) 1978-04-13 1991-12-31 Derivatives of carbazol-4-yloxy-propanol amine, process of their preparation and medicament containing these compounds
MX9203380A MX9203380A (es) 1978-04-13 1992-06-25 Derivados de carbazolil-(4)-oxi-propanolamina y composiciones farmaceuticas que los contienen.
LV930454A LV5234A3 (lv) 1971-10-29 1993-06-01 (Karbazolil-4-oksi)propanolamina atvasinajumu un to saju iegusanas panemiens (varianti)
LU88320C LU88320I2 (de) 1978-04-13 1993-06-22 Carvedilol (Dilatred /Dimitone)
NL930110C NL930110I2 (nl) 1978-04-13 1993-06-29 Carbazolyl-(4)-oxypropanolamine-derivaten, werkwijze ter bereiding daarvan en geneesmiddelen, die deze verbindingen bevatten.
LTRP1124A LT2628B (lt) 1978-04-13 1993-09-27 Karbazolil-(4)-oksi-propanolamino dariniu arba ju drusku gavimo budas (jo variantai)
BG098612A BG61419B2 (bg) 1978-04-13 1994-02-28 Производни на карбазолил-(4)-окси-пропаноламина,метод за получаването им и лекарствено средство,съдържащо тези съединения

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19782815926 DE2815926A1 (de) 1978-04-13 1978-04-13 Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel

Publications (1)

Publication Number Publication Date
DE2815926A1 true DE2815926A1 (de) 1979-10-18

Family

ID=6036838

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19782815926 Withdrawn DE2815926A1 (de) 1971-10-29 1978-04-13 Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE7979101063T Expired DE2960553D1 (en) 1978-04-13 1979-04-07 Derivatives of carbazolyl-4-oxypropanolamine, methods for their preparation and medicines containing them

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE7979101063T Expired DE2960553D1 (en) 1978-04-13 1979-04-07 Derivatives of carbazolyl-4-oxypropanolamine, methods for their preparation and medicines containing them

Country Status (23)

Country Link
US (1) US4503067A (enExample)
EP (1) EP0004920B1 (enExample)
JP (2) JPS54157558A (enExample)
AT (1) AT375639B (enExample)
AU (1) AU522975B2 (enExample)
BG (1) BG61419B2 (enExample)
CA (1) CA1129416A (enExample)
CS (2) CS227007B2 (enExample)
DD (1) DD143607A5 (enExample)
DE (2) DE2815926A1 (enExample)
DK (1) DK154555C (enExample)
ES (1) ES479396A1 (enExample)
FI (1) FI70406C (enExample)
HK (1) HK2385A (enExample)
HU (1) HU179433B (enExample)
IL (1) IL57020A (enExample)
LT (1) LT2628B (enExample)
LU (1) LU88320I2 (enExample)
MX (1) MX9203380A (enExample)
NL (1) NL930110I2 (enExample)
SG (1) SG52284G (enExample)
SU (1) SU810079A3 (enExample)
ZA (1) ZA791732B (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4985454A (en) * 1983-05-26 1991-01-15 Boehringer Mannheim Gmbh Process for the preparation of optically-active carbazole derivatives, new R- and S-carbazole derivatives and pharmaceutical compositions containing these compounds
EP0893440A1 (en) * 1997-07-22 1999-01-27 Roche Diagnostics GmbH Thermodynamically stable modification of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole, process for its preparation and pharmaceutical compositions containing it
EP0918055A1 (en) * 1997-11-24 1999-05-26 Egis Gyogyszergyar Rt. Process and intermediates for preparing 1-[9'H-carbazol-4'-yloxy]-3-[ 2''-(2'''- methoxy -phenoxy)-ethyl)-amino]-propan-2-ol[carvedilol]
US6730326B2 (en) 1997-07-22 2004-05-04 Roche Diagnostics Gmbh Thermodynamically stable modification of 1-(4-carbazolyl-oxy-3[2-(2-methoxyphenoxy)-ethylamino]-2-propanol process for its preparation and pharmaceutical compositions containing it
WO2004041783A1 (en) * 2002-11-08 2004-05-21 Zentiva, A.S. Process for preparation of carvedilol
RU2245875C2 (ru) * 1997-11-24 2005-02-10 Эгиш Дьёдьсердьяр Рт. Способ получения фармацевтического продукта

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3131146A1 (de) * 1981-08-06 1983-02-24 Boehringer Mannheim Gmbh, 6800 Mannheim Neue heteroaryloxypropanolamine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3300933A1 (de) * 1983-01-13 1984-07-19 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von d,l- und d-carazolol als antiglaukommittel sowie arzneimittel, die diese stoffe enthalten
GB9113802D0 (en) * 1991-06-26 1991-08-14 Smithkline Beecham Plc Medicaments
US5405863A (en) * 1992-12-01 1995-04-11 Smithkline Beecham Corporation Antioxidant cardioprotective use of, and method of treatment using, hydroxycarbazole compounds
ZA938897B (en) * 1992-12-01 1994-08-01 Smithkline Beecham Corp Antioxidant neuroprotective use of and method of treatment using hydroxycarbazole compounds
WO1994020096A1 (en) * 1993-03-05 1994-09-15 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beckman Corporation Limited Method of employing carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
US5308862A (en) * 1993-03-05 1994-05-03 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
US5393772A (en) * 1993-11-24 1995-02-28 Boehringer Mannheim Pharmaceuticals Corporation Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
ZA967892B (en) * 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
US6177430B1 (en) 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
DE19628335A1 (de) * 1996-07-13 1998-01-15 Boehringer Mannheim Gmbh Verwendung von Carbazolyl-(4)-oxy-propanolamin-Derivaten zur topischen Behandlung von peripheren Durchblutungsstörungen
AU4083097A (en) * 1996-08-23 1998-03-06 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership No. 1 Method for inhibiting the expression of fas
US5808080A (en) * 1996-09-05 1998-09-15 Eli Lilly And Company Selective β3 adrenergic agonists
DE69711519T2 (de) * 1996-09-05 2002-10-31 Eli Lilly And Co., Indianapolis Carbazolanaloge als selektive beta3-adrenergische Agonisten
WO1998015272A1 (en) * 1996-10-09 1998-04-16 BOEHRINGER MANNHEIM PHARMACEUTICALS CORP. - SMITHKLINE BEECHAM CORPORATION, LIMITED PARTNERSHIP No.1 Method for inhibiting stress-activated protein kinases
ZA989365B (en) * 1997-10-15 1999-04-15 Boehringer Mannheim Pharm Corp Preparation for treating alzheimer's disease
CN1285738A (zh) * 1997-11-12 2001-02-28 泊灵格曼海姆药品公司及史密斯克莱恩贝克曼公司 卡维地洛的新的口服剂型
CO5011072A1 (es) * 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
CA2326840C (en) * 1998-04-09 2007-08-07 Roche Diagnostics Gmbh Carvedilol-galenics
EP0968714A1 (de) * 1998-07-02 2000-01-05 Roche Diagnostics GmbH Verfahren zur Herstellung schnellauflösender pharmazeutischer Zubereitungen von schwerlöslichen Wirkstoffen
DE19833119A1 (de) * 1998-07-23 2000-01-27 Roche Diagnostics Gmbh Spritzfertige Injektionslösungen enthaltend Carvedilol
US6664284B2 (en) 1998-07-23 2003-12-16 Roche Diagnostics Gmbh Stabilized carvedilol injection solution
AU5251999A (en) 1998-08-04 2000-02-28 Wisconsin Alumni Research Foundation Method of reducing retinal ganglion cell degeneration
PE20001302A1 (es) 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
MY125942A (en) 1999-09-07 2006-09-29 Upjohn Co Aminoalkoxy carbazoles for the treatment of cns diseases
JP2003514019A (ja) 1999-11-15 2003-04-15 スミスクライン・ビーチャム・コーポレイション カルベジロールメタンスルホン酸塩
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
WO2001074356A1 (en) * 2000-04-03 2001-10-11 F. Hoffmann-La Roche Ag Concentrated solutions of carvedilol
DK174645B1 (da) * 2000-05-18 2003-08-04 Gea Farmaceutisk Fabrik As Fremgangsmåde og mellemprodukter til fremstillingen af 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxy-phenoxy)-ethylamino]-propan-2-ol, carvedilol og syreadditionssalte deraf
IL153688A0 (en) 2000-06-28 2003-07-06 Teva Pharma Carvedilol
EP1655285A1 (en) * 2000-06-28 2006-05-10 Teva Pharmaceutical Industries Ltd. Method for preparation of a crystalline form of carvedilol (form II)
GB0106953D0 (en) * 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
US20050009897A1 (en) * 2001-04-02 2005-01-13 Karen Anderson Method of treatment
IN191028B (enExample) * 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
JP2004534840A (ja) * 2001-07-13 2004-11-18 スミスクライン・ビーチャム・コーポレイション カルベジロール多型体
WO2003017046A2 (en) * 2001-08-14 2003-02-27 Variant Holdings, Llc. System for marketing goods and services utilizing computerized central and remote facilities
WO2003024430A1 (en) * 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
WO2003029214A1 (en) * 2001-09-28 2003-04-10 F. Hoffmann-La Roche Ag Pseudopolymorphic forms of carvedilol
WO2003028718A1 (en) * 2001-10-01 2003-04-10 Smithkline Beecham Corporation Novel formulations of carvedilol
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
PL371409A1 (en) * 2002-01-15 2005-06-13 Teva Pharmaceutical Industries Ltd. Crystalline solids of carvedilol and processes for their preparation
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
JP2006500320A (ja) * 2002-04-30 2006-01-05 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール一クエン酸塩一水和物
JP2005530746A (ja) * 2002-05-03 2005-10-13 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロールファーマソルブ溶媒和物
AU2003231306A1 (en) * 2002-05-03 2003-11-17 Smithkline Beecham Pharmco Puerto Rico, Inc. Carvedilol formulations
MXPA04012923A (es) 2002-06-27 2005-03-31 Sb Pharmco Inc Sales de fosfato de carvedilol y/o solvatos de las mismas, composiciones correspondientes y/o metodos de tratamiento.
AU2003251627A1 (en) 2002-06-27 2004-01-19 Sb Pharmco Puerto Rico Inc. Carvedilol hydrobromide
US20040152756A1 (en) * 2002-07-15 2004-08-05 Wei Chen Carvedilol polymorph
US20060013877A1 (en) * 2002-07-22 2006-01-19 Nanohybrid Co., Ltd. Hybrid of itraconazole, cyclosporine or carvedilol with a layered silicate and a process for preparing the same
EP1545519B1 (en) 2002-08-19 2011-03-23 Pfizer Inc. Combination therapy for hyperproliferative diseases
US6632832B1 (en) 2002-09-10 2003-10-14 Dabur Research Foundation Anti-cancer activity of carvedilol and its isomers
AU2003275953A1 (en) * 2002-11-08 2004-06-07 Egalet A/S Controlled release carvedilol compositions
WO2004094378A1 (en) * 2003-04-21 2004-11-04 Matrix Laboratories Ltd Process for the preparation of carvedilol form-ii
CN1812983A (zh) * 2003-05-30 2006-08-02 兰贝克赛实验室有限公司 取代的吡咯衍生物及其作为hmg－co抑制剂的用途
US7482471B2 (en) * 2003-06-20 2009-01-27 Sun Pharmaceutical Industries Limited Process for preparation of 1-[9H-carbazol-4-yloxy]-3-[{2-(2-(-methoxy)phenoxy)-ethyl}-amino]-propan-2-ol
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
US20050169994A1 (en) * 2003-11-25 2005-08-04 Burke Matthew D. Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
JP2007512372A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール塩、対応する組成物、送達および／または治療方法
WO2005051322A2 (en) 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Controlled release pharmaceutical formulations comprising carvedilol, free based and its salts
WO2005115981A2 (en) * 2004-04-22 2005-12-08 Usv Limited A process for the preparation of 1-(9h-carbazol-4-yloxy)-3-2-(-methoxyphenoxy)-ethyl amino-propan-2-ol
GB0411273D0 (en) * 2004-05-20 2004-06-23 Cipla Ltd Process and product
US20080255134A1 (en) * 2004-11-30 2008-10-16 Artesian Therapeutics, Inc. Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase
CA2589699A1 (en) * 2004-12-09 2006-06-15 Zach System S.P.A. Process for the preparation of carvedilol and its enantiomers
US20070027202A1 (en) * 2005-06-07 2007-02-01 Ashok Kumar Process for the preparation of carvedilol and its salts
EP1781611A1 (en) * 2005-06-09 2007-05-09 Teva Pharmaceutical Industries Ltd. Crystalline forms of carvedilol and processes for their preparation
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
CA2625219A1 (en) 2005-10-13 2007-04-19 Orchid Research Laboratories Limited Heterocyclic compounds as pstat3/il-6 inhibitors
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
SG166829A1 (en) * 2005-11-08 2010-12-29 Ranbaxy Lab Ltd Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
WO2008020314A2 (en) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
US8703804B2 (en) 2006-03-26 2014-04-22 Uti Limited Partnership Ryanodine receptor inhibitors and methods relating thereto
WO2008002683A2 (en) * 2006-06-28 2008-01-03 Teva Pharmaceutical Industries Ltd. Polymorphous forms of carvedilol phosphate
WO2008010087A2 (en) * 2006-07-14 2008-01-24 Ranbaxy Laboratories Limited Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof
WO2008038301A1 (en) * 2006-09-26 2008-04-03 Morepen Laboratories Limited A process for the preparation of carvedilol
US20090028935A1 (en) * 2006-12-01 2009-01-29 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
US20080292695A1 (en) * 2006-12-01 2008-11-27 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
WO2008084494A1 (en) * 2007-01-08 2008-07-17 Matrix Laboratories Limited Novel polymorphic forms of carvedilol dihydrogen phosphate and process for preparing the same
EP2104493A2 (en) * 2007-01-16 2009-09-30 Egalet A/S Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
CZ302357B6 (cs) * 2007-01-26 2011-03-30 Zentiva, A. S. Zpusob cištení Carvedilolu
US20080207726A1 (en) * 2007-02-26 2008-08-28 Santiago Ini Process for the purification of carvedilol or its salts thereof
US20080249317A1 (en) * 2007-04-04 2008-10-09 Apotex Inc. Novel amorphous form of carvedilol phosphate and processes for the preparation thereof
WO2008142703A1 (en) * 2007-05-17 2008-11-27 Wanbury Limited A novel cost effective process for production of carvedilol phosphate
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
US8278461B2 (en) * 2007-08-21 2012-10-02 Lupin Limited Stable amorphous form of carvedilol dihydrogen phosphate with stabilizer
WO2009035535A2 (en) * 2007-09-07 2009-03-19 Scinopharm Taiwan Ltd. Method of crystallizing carvedilol phosphate and the product thereof
US20090076116A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched carvediolo
US20090111998A1 (en) * 2007-10-25 2009-04-30 Srinivas Reddy Gade Process for the preparation of carvedilol dihydrogen phosphate hemihydrate and pharmaceutical compositions thereof
US8889728B2 (en) * 2008-03-04 2014-11-18 Lupin Limited Stable pharmaceutical compositions of carvedilol
WO2009115902A1 (en) * 2008-03-19 2009-09-24 Cadila Pharmaceuticals Ltd. Process for the preparation of carvedilol via silyl protection of substituted amine
WO2009115906A2 (en) * 2008-03-19 2009-09-24 Cadila Pharmaceuticals Ltd. An improved process for preparation of carvedilol involving halohydrin derivative
US20110015247A1 (en) * 2008-04-04 2011-01-20 Shodhana Laboratories Limited Novel crystalline form of carvedilol dihydrogen phosphate and related processes
US7763645B2 (en) * 2008-05-23 2010-07-27 Wanbury Limited Carvedilol dihydrogen phosphate monohydrate
WO2010092589A2 (en) * 2008-05-26 2010-08-19 Alkem Laboratories Ltd. Process for preparation of amorphous carvedilol phosphate
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
WO2010149169A2 (en) 2009-06-24 2010-12-29 Egalet A/S Controlled release formulations
TWI415604B (zh) 2009-09-29 2013-11-21 Tsh Biopharm Corp Ltd 調控釋放卡菲蒂羅劑型
US20110229564A1 (en) * 2010-03-22 2011-09-22 Amneal Pharmaceuticals, L.L.C. Pharmaceutical Compositions Of Carvedilol Salts And Process For Preparation Thereof
BR112014014480A2 (pt) 2011-12-16 2017-06-13 3M Innovative Properties Co derivados de bisanidro-hexitol que contêm oxirano e usos dos mesmos
US9549899B2 (en) 2012-07-06 2017-01-24 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
US8492426B1 (en) * 2012-07-12 2013-07-23 Anis Ahmad Use of carvedilol for treatment of diabetes mellitus
SG11201507496UA (en) 2013-04-17 2015-11-27 Pfizer N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
US10357476B1 (en) 2018-10-30 2019-07-23 Anis Ahmad Method for treating coronary artery disease
US11248001B2 (en) 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
CN111170997A (zh) * 2019-12-31 2020-05-19 广州医科大学 咔唑类化合物及其制备方法和应用
CN113372260A (zh) * 2021-07-05 2021-09-10 大连蒙迪科技有限公司 一种卡维地洛杂质的合成方法
CN115960032A (zh) * 2021-10-08 2023-04-14 复旦大学 具有β-arrestin偏向性激动活性的芳氧丙醇胺类β-肾上腺素受体配基及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1834015A (en) * 1929-06-29 1931-12-01 Gen Aniline Works Inc Manufacture of hydroxy carbazoles
DE1152107B (de) * 1956-06-27 1963-08-01 Chem Fab Promonta G M B H Verfahren zur Herstellung von basisch substituierten Carbazolderivaten und deren Salzen
US3932424A (en) * 1970-06-15 1976-01-13 Richardson-Merrell Inc. Bis-basic ethers of carbazole
BE789072A (fr) * 1971-09-23 1973-03-21 Astra Laekemedel Ab Composes abaissant le taux de lipides du serum et leur obtention
AT336176B (de) * 1971-12-10 1977-04-25 Sandoz Ag Verfahren zur herstellung eines pharmazeutischen praparates
US3975398A (en) * 1973-08-01 1976-08-17 Boehringer Mannheim G.M.B.H. 9-Substituted 3-aminocarbazole compounds
DE2339396C2 (de) * 1973-08-03 1984-06-28 Boehringer Mannheim Gmbh, 6800 Mannheim N-substituierte 1-Amino-3-phenoxypropan-2-ole, deren Salze, Verfahren zu deren Herstellung sowie Arzneimittel, die diese Verbindungen enthalten
DE2424523A1 (de) * 1974-05-21 1975-12-11 Boehringer Mannheim Gmbh Neue 1,2,3,4-tetrahydrocarbazol-derivate und verfahren zu deren herstellung
DE2454406A1 (de) * 1974-11-16 1976-05-20 Boehringer Mannheim Gmbh Neue aminopropanol-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4076829A (en) * 1974-11-16 1978-02-28 Boehringer Mannheim Gmbh Aminopropanol compounds and compositions for the treatment of cardiac and circulatory diseases
US4152446A (en) * 1974-11-16 1979-05-01 Boehringer Mannheim Gmbh Aminopropanol compounds and compositions for the treatment of cardiac and circulatory diseases
GB1508208A (en) * 1975-12-05 1978-04-19 Ici Ltd Amide derivatives
US4115409A (en) * 1975-12-05 1978-09-19 Imperial Chemical Industries Limited Alkanolamine derivatives

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4985454A (en) * 1983-05-26 1991-01-15 Boehringer Mannheim Gmbh Process for the preparation of optically-active carbazole derivatives, new R- and S-carbazole derivatives and pharmaceutical compositions containing these compounds
US5071868A (en) * 1983-05-26 1991-12-10 Boehringer Mannheim Gmbh Process for the preparation of optically-active carbazole derivatives, new r- and s-carbazole derivatives and pharmaceutical compositions containing these compounds
EP0893440A1 (en) * 1997-07-22 1999-01-27 Roche Diagnostics GmbH Thermodynamically stable modification of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole, process for its preparation and pharmaceutical compositions containing it
WO1999005105A1 (en) * 1997-07-22 1999-02-04 Roche Diagnostics Gmbh Thermodynamically stable modification of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole, process for its preparation and pharmaceutical compositions containing it
RU2202542C2 (ru) * 1997-07-22 2003-04-20 Рош Диагностикс Гмбх Термодинамически стабильная модификация (±)1-(4-карбазолилокси)-3-[2-(2-метоксифенокси)этиламино]-2-пропанола , способ ее получения и содержащая ее фармацевтическая композиция
US6730326B2 (en) 1997-07-22 2004-05-04 Roche Diagnostics Gmbh Thermodynamically stable modification of 1-(4-carbazolyl-oxy-3[2-(2-methoxyphenoxy)-ethylamino]-2-propanol process for its preparation and pharmaceutical compositions containing it
CZ296947B6 (cs) * 1997-07-22 2006-08-16 Roche Diagnostics Gmbh Modifikace (+-)1-(4-karbazolyloxy)-3-[2-(2-methoxyfenoxy)ethylamino]-2-propanolu, zpusob její prípravy a izolace, farmaceutický prostredek s jejím obsahem a jeho pouzití
EP0918055A1 (en) * 1997-11-24 1999-05-26 Egis Gyogyszergyar Rt. Process and intermediates for preparing 1-[9'H-carbazol-4'-yloxy]-3-[ 2''-(2'''- methoxy -phenoxy)-ethyl)-amino]-propan-2-ol[carvedilol]
EP1142873A3 (en) * 1997-11-24 2003-09-10 Egis Gyogyszergyar Rt. Process for preparing 1-[9'H-carbazol-4'-yloxy]-3-[ 2''-(2'''- methoxy -phenoxy)-ethyl -amino]-propan-2-ol[carvedilol]
EP1142874A3 (en) * 1997-11-24 2003-10-22 Egis Gyogyszergyar Rt. Intermediates for preparing the R or S enantiomer of 1-[9'H-carbazol-4'-yloxy]-3-[ 2''-(2'''- methoxy -phenoxy)-ethyl -amino]-propan-2-ol[carvedilol]
RU2245875C2 (ru) * 1997-11-24 2005-02-10 Эгиш Дьёдьсердьяр Рт. Способ получения фармацевтического продукта
WO2004041783A1 (en) * 2002-11-08 2004-05-21 Zentiva, A.S. Process for preparation of carvedilol

Also Published As

Publication number Publication date
FI70406C (fi) 1986-09-19
AU522975B2 (en) 1982-07-08
FI70406B (fi) 1986-03-27
SG52284G (en) 1985-03-29
US4503067A (en) 1985-03-05
DK154555B (da) 1988-11-28
EP0004920B1 (de) 1981-08-05
CS227007B2 (en) 1984-04-16
AT375639B (de) 1984-08-27
MX9203380A (es) 1992-09-01
JPS54157558A (en) 1979-12-12
LU88320I2 (de) 1994-05-04
LT2628B (lt) 1994-04-25
JPH0123462B2 (enExample) 1989-05-02
NL930110I1 (nl) 1993-10-18
CA1129416A (en) 1982-08-10
FI791142A7 (fi) 1979-10-14
BG61419B2 (bg) 1997-07-31
AU4582079A (en) 1979-10-18
HK2385A (en) 1985-01-18
IL57020A0 (en) 1979-07-25
ES479396A1 (es) 1980-04-16
DK141979A (da) 1979-10-14
SU810079A3 (ru) 1981-02-28
NL930110I2 (nl) 1994-12-01
DK154555C (da) 1989-06-19
ZA791732B (en) 1980-05-28
JPS63258416A (ja) 1988-10-25
ATA276279A (de) 1984-01-15
CS420091A3 (en) 1992-04-15
DD143607A5 (de) 1980-09-03
DE2960553D1 (en) 1981-11-05
EP0004920A1 (de) 1979-10-31
HU179433B (en) 1982-10-28
IL57020A (en) 1982-07-30

Similar Documents

Publication Publication Date Title
EP0004920B1 (de) Carbazolyl-(4)-oxy-propanolamin-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0014951B1 (de) Heterocyclische Oxypropanolamin-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
JP2637737B2 (ja) 新規な薬剤
CH624102A5 (enExample)
DE3631824A1 (de) Cycloalkano(1.2-b)indol-sulfonamide
EP0529462A1 (de) Benzodioxanderivate
DE3114239C2 (de) N↑4↑-Carbamoylpiperazinpropanolderivate, Verfahren zu ihrer Herstellung und pharmazeutisches Mittel
JPS6215062B2 (enExample)
DE3411993A1 (de) Substituierte benzopyrane, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimittel
EP0199262A2 (de) Fluorierte Benzyltriazolverbindungen
EP0008645B1 (de) Alkoxyphenylpyrrolidone, Verfahren zu ihrer Herstellung und Arzneimittel auf Basis dieser Verbindungen
DE69719511T2 (de) Antivirale 2,4-pyrimidindion-derivate und verfahren zu ihrer herstellung
EP0065295A1 (de) Substituierte Tryptaminderivate von Thienyloxypropanolaminen, Verfahren zu ihrer Herstellung, pharmazeutische Präparate auf Basis dieser Verbindungen sowie ihre Verwendung
EP0041233B1 (de) Substituierte Phenoxy-aminopropanol-Derivate, Zwischenprodukte und Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
EP0303920B1 (de) Neue Benzofuranderivate und diese enthaltende therapeutische Mittel
JPS648621B2 (enExample)
EP0586405B1 (de) NEUE IN 4-STELLUNG DURCH ARYL ODER N-HETEROARYL SUBSTITUIERTE 2H-BENZO[b]PYRAN-DERIVATE, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG SOWIE DIE VERBINDUNGEN ENTHALTENDE ZUBEREITUNGEN
DE2740678A1 (de) 1-amino-2-hydroxy-3-heterocycloxypropane
DE2217329A1 (de) Benzofuranderivate
EP0029992B1 (de) Neue Aminopropanolderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE2914166A1 (de) Arylsubstituierte furane und verfahren zu ihrer herstellung
EP0030030A1 (de) Derivate des 2-Amino-äthanols, Verfahren zu ihrer Herstellung, pharmazeutische Präparate enthaltend solche Verbindungen und Verwendung von letzteren
CN113501795A (zh) 一种新型重度抑郁症治疗药物伏硫西汀的制备方法
US5391570A (en) Aminomethyl-benzodioxane and benzopyran serotonergic agents
DD210266A5 (de) Verfahren zur herstellung von 3-(ureidocyclohexylamino)-propan-1,2-diolderivaten

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee